

SY-01

Room A October 2 (Tue.) 10 : 00~12 : 00

MDO 50th Anniversary #1. Drug metabolizing enzymes and transporters: regulation, role in disease, and importance for drug disposition and action.

Chair : Rita Bernhardt Universität des Saarlandes, Lehrstuhl für Biochemie,
Germany

Yoshiaki Fujii-Kuriyama Tohoku University

SY-01-01

Xenobiotic receptors: Mechanism of PPAR α -activated hepatocyte proliferation and carcinogenesis

Frank J. Gonzalez

Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, and National Institutes of Health, MD, USA



Positions and Employment

- | | |
|-----------|---|
| 1975-1977 | Graduate Student, Graduate Research Associate, Department of Microbiology, University of South Florida, Tampa, Florida |
| 1977-1981 | Graduate Student, Department of Oncology, University of Wisconsin, Madison, Wisconsin McArdle Laboratory for Cancer Research, |
| 1981-1982 | Postdoctoral Fellow, McArdle Laboratory for Cancer Research |
| 1982-1984 | Staff Fellow, Laboratory of Developmental Pharmacology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland |
| 1984-1988 | Senior Staff Fellow, Laboratory of Molecular Carcinogenesis, National Cancer Institute, National Institutes of Health |
| 1988-1990 | Supervisory Research Chemist, GM-14 (academic tenure equivalent) |
| 1990-1996 | GM-15 (academic full professor equivalent) |
| 1996- | Chief, Laboratory of Metabolism, Center for Cancer Research, NCI |

SY-01-02**Phenobarbital drives CAR into the future of the nuclear receptor world**

Masahiko Negishi

National Institute of Environmental Health Sciences, NIH, NC USA



He has been Principle Investigator heading the Pharmacogenetics section since 1983 at National Institute of Environmental Health Sciences, National Institute of Health, NIH, USA. He received his Doctor in Science in Biochemistry from the Institute of Protein Research at Osaka University in Japan and carried out postdoctoral training in the Department of Cell Biology at New York University and National Institute of Child Health and Human Development, NIH. His major research interests lie in the structure-activity relationship of drug-metabolizing enzymes and the regulation mechanisms of drug-induced gene expression.

SY-01-03**From microsomal cytochromes and drug oxidations to P450 ERAD: Fascinating travels in and out of the ER**

M. Almira Correia

Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA USA



She received B. Pharm (University of Bombay), and PhD (Pharmacology/Biochemistry; University of Minnesota, Minneapolis). After postdoctoral training at UCSF, she joined the UCSF Department of Cellular & Molecular Pharmacology, School of Medicine, where she is currently Professor of Cellular & Molecular Pharmacology, with joint faculty positions in the UCSF Departments of Pharmaceutical Chemistry and Bioengineering and Therapeutic Sciences. Her long-standing research interests include: Assembly, structure-function relationships, mechanism-based inactivation, and heme regulation of hepatic cytochromes P450, and the regulation and mechanistic characterization of P450 proteolytic turnover and its clinical relevance. She also holds major research interests in drug-induced liver toxicity and in the regulation and dysregulation of hepatic heme synthesis and metabolism, with a special interest in the biochemical mechanisms of acute hepatic porphyrias.

SY-01-04

PBPK analyses of interplay between uptake, efflux transporters and metabolizing enzymes

Yuichi Sugiyama
RIKEN Innovation Center, RIKEN



He started working as the Head of Sugiyama Laboratory in RIKEN, Japan since 2012. He had been the Professor, Department of Molecular Pharmacokinetics at the University of Tokyo since 1991, retired from the University in 2012 and moved to RIKEN. He has made and continues to make internationally acclaimed contributions to the pharmaceutical sciences in diverse areas. These include physiologically-based pharmacokinetic modelling, the prediction of drug clearance from in vitro data, the quantitative prediction of transporter and enzyme mediated drug-drug interactions based on in vitro studies. His work is internationally recognized by many awards, including AAPS Distinguished Pharmaceutical Scientist Award, 2003, FIP Hoest Madsen Medal in 2009, "Medal with Purple Ribbon" given by Japanese Government in 2010, B.B.Brodie Award from ASPET in 2012, R.T. Williams Distinguished Scientific Achievement Award (ISSX) in 2013 and Rawls-Palmer Progress in Medicine Award from ASCPT in 2014. He was also the president of both "International society for the study of xenobiotics (ISSX)" and JSSX in 2006-2007.